CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL

• Status: Recruiting
• Trial end date: 2029-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A prospective study on the efficacy of modified ALCL99 regimens in the treatment of the current Chinese pediatric and adolescent high-risk ALCL and compared with our historical data.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Cancer Group, China
• Collaborators: 1st Affiliated Hospital of Zhengzhou University; Nanjing Children's Hospital; Qilu Hospital of Shandong University; Shanghai Children's Medical Center; Tianjin Cancer Hospital; West China Second University Hospital; Xiangya Hospital

Criteria

Inclusion Criteria:

• Patient must be ≤ 18 years at the time of diagnosis

• Newly diagnosed patients with histologically confirmed high-risk anaplastic large cell lymphoma

• No congenital immunodeficiency, HIV infection, or prior organ transplant

Exclusion Criteria:

• Patients have received prior cytotoxic chemotherapy/target therapy/radiation, if any steroid applied, total prior steroids dosage > Dexamethasone 40 mg/m2 for the current diagnosis or any cancer

• Patients have overwhelming infection, and a life expectancy of < 2 weeks